home / stock / vigl / vigl news

VIGL News and Press, Vigil Neuroscience Inc. From 03/20/24

Stock Information
Company Name: Vigil Neuroscience Inc.
Stock Symbol: VIGL
Market: NASDAQ
Website: vigilneuro.com
Menu
VIGL VIGL Quote VIGL Short VIGL News VIGL Articles VIGL Message Board
Get VIGL Alerts

News, Short Squeeze, Breakout and More Instantly...
VIGL - Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F...
VIGL - Expected US Company Earnings on Tuesday, March 19th, 2024

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

VIGL - Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 202...

VIGL - Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph...
VIGL - Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented preclinical data on the profile of VG-3927 i...

VIGL - Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Poster highlights clinical overlap of ALSP and multiple sclerosis (MS) and details patients’ barriers to genetic testing WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing...

VIGL - Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph...
VIGL - COMM, NKTX and AVIR are among after hour movers

2024-01-08 16:53:20 ET Gainers: Universe Pharmaceuticals  ( UPC ) +13% . MaxCyte ( MXCT ) +12% . WISeKey International Holding  ( WKEY ) +8% . Alset Capital Acquisition  ( ACAX ) +7% . Atea Pharmaceuticals ( AVIR ) +...

VIGL - Vigil Neuroscience remains on track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024

2024-01-04 09:26:56 ET More on Vigil Neuroscience Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway Vigil Neuroscience reports interim Phase 2 data for ALSP drug candidate Vigil Neuroscience GAAP EPS of -$0.53 beats by $0.03 For fur...

VIGL - Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

- On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 - - Extends projected cash runway into second half of 2025 - - Company to present at J.P. Morgan Healt...
Previous 10 Next 10